Zurcher Kantonalbank (Zurich Cantonalbank) Savara Inc Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $34.1 Billion
- Q4 2024
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Savara Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 63,616 shares of SVRA stock, worth $171,127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,616
Previous 44,008
44.56%
Holding current value
$171,127
Previous $186,000
4.84%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SVRA
# of Institutions
141Shares Held
158MCall Options Held
55.6KPut Options Held
600-
Nea Management Company, LLC Timonium, MD24.5MShares$65.8 Million5.37% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$39.2 Million12.07% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$33.3 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$29 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$23.3 Million1.59% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $307M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.